Get the Stockscreener App
54.46
0.89%
-0.49
After Hours:
54.39
-0.07
-0.13%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $54.46, with a volume of 13.73M.
It is down -0.89% in the last 24 hours and down -6.46% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$54.95
Open:
$54.78
24h Volume:
13.73M
Relative Volume:
1.18
Market Cap:
$111.21B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
15.29
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-6.15%
1M Performance:
-6.46%
6M Performance:
+12.87%
1Y Performance:
+11.62%
1-Day Range:
$54.20
$55.59
1-Week Range:
$54.20
$58.80
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.46 | 112.21B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,064.15 | 965.04B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
222.89 | 538.04B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.40 | 376.20B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.65 | 284.45B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
177.45 | 278.70B | 60.48B | 10.40B | 8.05B | 3.3297 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - MarketBeat
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors (NYSE:BMY) - Seeking Alpha
BMY: Positive Interim Results for Bristol Myers' Iza-bren in Can - GuruFocus
Bristol-Myers Squibb CoIzalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC - TradingView
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook - Yahoo Finance
Bristol-Myers Squibb’s Stock Looks Cheap on the Surface, but Hidden Risks Lurk Beneath - NAI500
Bristol Myers' Growth Portfolio Just Overtook The Legacy One - Seeking Alpha
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks - The Motley Fool
Bristol-Myers Squibb Co (BMY) Shares Fall 3.9% -- What GF Score of 77 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb slips as investors weigh long-term pricing and patent-cliff risks despite FDA review news - Quiver Quantitative
Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): focus on Bristol Myers deal and China A-share - AD HOC NEWS
Bristol Myers Squibb CEO on cancer developments in the pipeline - CNBC
Cullen Enhanced Equity Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call - Benzinga
BioNTech (BNTX) and BMS show high NSCLC response rates with pumitamig - Stock Titan
BMY: FDA Reviews Camzyos for Adolescent Hypertrophic Cardiomyopa - GuruFocus
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1 - Yahoo Finance
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma - BioSpace
FDA accepts Bristol Myers Squibb adolescent oHCM application By Investing.com - Investing.com Canada
FDA accepts Bristol Myers Squibb adolescent oHCM application - Investing.com
US big pharma vents over Australia’s drug pricing and approvals - AFR
Peapack Gladstone Financial Corp Has $24.27 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Nomura Asset Management Co. Ltd. Decreases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
MUFG Securities EMEA plc Raises Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
BioNTech SE stock (US09075V1026): ASCO lung cancer data with Bristol Myers Squibb puts oncology pipe - AD HOC NEWS
Bristol-Myers Squibb (BMY) Stock Analysis: Navigating a 10.32% Potential Upside Amidst Healthcare Innovation - DirectorsTalk Interviews
Encouraging efficacy data for BioNTech and BMS’s pumitamig shown at ASCO - The Pharma Letter
Black Swift Group LLC Purchases New Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMY: Promising Phase 2 Results for Pumitamig in Lung Cancer Trea - GuruFocus
BMY Shows Promising Results in Lung Cancer Trial - GuruFocus
Railway Pension Investments Ltd Has $63.89 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Impact Partnership Wealth LLC - MarketBeat
ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach - Fierce Biotech
BioNTech and Bristol Myers Squibb Announce Promising Interim Data for Pumitamig Combined with Chemotherapy in First-Line Non-Small Cell Lung Cancer at ASCO 2026 - Quiver Quantitative
Experimental BioNTech lung cancer drug shows high responses in early trial - Stock Titan
Norges Bank Acquires Shares of 36,100,698 Bristol Myers Squibb Company $BMY - MarketBeat
Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Fideuram Asset Management Ireland dac Takes Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company stock (US0897961004): ASCO 2026 mezigdomide data in focus after Phase 3 - AD HOC NEWS
Positive Data for Mezigdomide Boosts Bristol Myers Squibb (BMY) and C4 Therapeutics (C FOUR) - GuruFocus
Bristol Myers Squibb (BMY) Reports Positive Results for Mezigdom - GuruFocus
Bristol Myers unveils data for one of its next-gen blood cancer drugs - BioPharma Dive
Texas comptroller recommends Bristol Myers Squibb's $1B manufacturing plant for tax break - KHOU
Bristol-Myers multiple myeloma data boosts C4 (BMY:NYSE) - Seeking Alpha
BMS touts positive mezigdomide results at ASCO - The Pharma Letter
ASCO: BMS’s Mezigdomide More Than Doubles PFS In Relapsed/Refractory Myeloma - Citeline News & Insights
Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside - TipRanks
BMS’ mezigdomide doubles PFS in multiple myeloma - BioWorld News
ASCO: BMS hails "compelling" phase 3 celmod readout - pharmaphorum
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):